Cytokinetics Appoints James M. Daly to Board of Directors

Cytokinetics appointed James M. Daly to its Board of Directors, enhancing its biopharmaceutical expertise.

Quiver AI Summary

Cytokinetics, Incorporated announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. With over 30 years of experience in the biopharmaceutical industry, particularly in commercialization, Daly previously served as Chief Commercial Officer at Incyte Corporation, where he oversaw the launch of Jakafi® and developed global commercial capabilities. He also held senior positions at Amgen and began his career at GlaxoSmithKline. Cytokinetics is focused on advancing treatments for cardiac muscle dysfunction and preparing for the potential commercialization of aficamten, a cardiac myosin inhibitor, following promising trial results.

Potential Positives

The appointment of James M. Daly to the Board of Directors brings significant expertise in biopharmaceutical commercialization, which may enhance the company's strategic direction.
Mr. Daly's experience with successful commercial launches of therapies, including at Incyte and Amgen, positions him to contribute valuable insights as Cytokinetics advances toward commercialization of new medicines.
The timing of Mr. Daly's appointment aligns with Cytokinetics' efforts to prepare for potential regulatory approvals, indicating a proactive step in strengthening the leadership team for future growth.
Cytokinetics' ongoing commitment to develop innovative therapies for cardiac muscle dysfunction is reinforced by this Board addition, exemplifying its focus on patient care and scientific innovation.

Potential Negatives

Appointment of James M. Daly may indicate the company is seeking operational improvements or expertise in commercialization due to previous challenges, potentially reflecting a need for stronger leadership during critical phases of development and commercialization.

FAQ

Who is James M. Daly?

James M. Daly is the newly appointed member of Cytokinetics' Board of Directors with over 30 years of biopharmaceutical experience.

What is Cytokinetics' main focus?

Cytokinetics focuses on developing innovative medicines for patients with diseases related to cardiac muscle dysfunction.

What experience does Mr. Daly bring to Cytokinetics?

Mr. Daly has extensive experience in commercial launches and leadership roles at companies like Incyte and Amgen.

What is aficamten?

Aficamten is a cardiac myosin inhibitor being developed for regulatory approval following promising Phase 3 trial results.

Where can I find more information about Cytokinetics?

Additional information about Cytokinetics can be found on their official website: www.cytokinetics.com.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$CYTK Congressional Stock Trading

Members of Congress have traded $CYTK stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $CYTK stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/11 and 1 sale worth up to $15,000 on 06/17.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$CYTK Insider Trading Activity

$CYTK insiders have traded $CYTK stock on the open market 45 times in the past 6 months. Of those trades, 0 have been purchases and 45 have been sales.

Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:

ROBERT I BLUM (President & CEO) has made 0 purchases and 15 sales selling 148,361 shares for an estimated $6,082,894.
ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 9 sales selling 70,548 shares for an estimated $2,958,653.
FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 15 sales selling 39,066 shares for an estimated $1,531,882.
WENDALL WIERENGA sold 20,000 shares for an estimated $769,200
JOHN T HENDERSON sold 3,190 shares for an estimated $123,325
EDWARD M. MD KAYE sold 3,636 shares for an estimated $116,715
ROBERT ARTHUR HARRINGTON has made 0 purchases and 2 sales selling 1,350 shares for an estimated $55,993.
MUNA BHANJI sold 1,454 shares for an estimated $43,227

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$CYTK Hedge Fund Activity

We have seen 169 institutional investors add shares of $CYTK stock to their portfolio, and 213 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 7,647,189 shares (+76.8%) to their portfolio in Q2 2025, for an estimated $252,663,124
MARSHALL WACE, LLP removed 2,007,567 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $66,330,013
POINT72 ASSET MANAGEMENT, L.P. removed 1,722,984 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $56,927,391
WESTFIELD CAPITAL MANAGEMENT CO LP removed 1,310,336 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $43,293,501
HOOD RIVER CAPITAL MANAGEMENT LLC removed 1,256,580 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $41,517,403
DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,160,315 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $38,336,807
JANUS HENDERSON GROUP PLC removed 1,007,582 shares (-95.3%) from their portfolio in Q2 2025, for an estimated $33,290,509

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CYTK Analyst Ratings

Wall Street analysts have issued reports on $CYTK in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citigroup issued a "Buy" rating on 08/08/2025
JP Morgan issued a "Overweight" rating on 06/09/2025
Mizuho issued a "Outperform" rating on 05/29/2025
Needham issued a "Buy" rating on 05/14/2025
Barclays issued a "Overweight" rating on 05/08/2025
RBC Capital issued a "Outperform" rating on 05/07/2025
HC Wainwright & Co. issued a "Buy" rating on 04/21/2025

To track analyst ratings and price targets for $CYTK, check out Quiver Quantitative's $CYTK forecast page.

$CYTK Price Targets

Multiple analysts have issued price targets for $CYTK recently. We have seen 11 analysts offer price targets for $CYTK in the last 6 months, with a median target of $77.0.

Here are some recent targets:

David Lebowitz from Citigroup set a target price of $77.0 on 08/08/2025
Tessa Romero from JP Morgan set a target price of $53.0 on 06/09/2025
Salim Syed from Mizuho set a target price of $84.0 on 05/29/2025
Serge Belanger from Needham set a target price of $72.0 on 05/14/2025
Gena Wang from Barclays set a target price of $53.0 on 05/08/2025
Leonid Timashev from RBC Capital set a target price of $80.0 on 05/07/2025
Ashwani Verma from UBS set a target price of $41.0 on 05/02/2025

Full Release

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company’s Board of Directors.

“Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We are pleased to welcome him to our Board and look forward to his contributions and oversight as our company advances toward becoming a fully integrated commercial organization.”

Most recently, Mr. Daly served as the Chief Commercial Officer at Incyte Corporation where he led the launch of Jakafi® (ruxolitinib) and oversaw development of the company’s global commercial capabilities. Previously, he spent 10 years at Amgen where he held multiple senior leadership positions, including Senior Vice President of North America Commercial Operations, and launched several successful medicines including Neulasta®, Xgeva®, Nplate® and Vectibix®. He began his career at GlaxoSmithKline, serving in escalating positions of seniority over his 16-year tenure with the company. He earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, SUNY. Mr. Daly currently serves on the Boards of Madrigal Pharmaceuticals, argenx SE, and Acadia Pharmaceuticals.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten , a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten , a cardiac myosin inhibitor with a mechanism of action distinct from aficamten , for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube .

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757